Daniel Getts

Most US biotech entrepreneurs and investors don’t consider Australia a thriving global hub. But there are compelling reasons to take another look at what’s happening there now. Australia has become more attractive based on its willingness to allow fast, affordable clinical trials to help early-stage developers gather human data on new drug candidates. That low-cost, high-speed, high-quality early development capability... Read More